Impurity Profiling: Why Reference Standards Matter in API Manufacturing

The ICH Thresholds in Plain English

Below the reporting threshold (typically 0.05% for most APIs), you do not even need to disclose an impurity. Between reporting and identification (0.10%), you must report but not yet characterise. Above identification, you must structurally identify the impurity. Above the qualification threshold (0.15%), you must demonstrate it is safe — usually by toxicology data or by showing it is present in the original innovator product at the same or higher level.

What a Reference Standard Does

To identify an impurity by HPLC, you need something to compare it against — a known, characterised sample of that exact compound with documented purity. That is a reference standard. Without it, you have an unknown peak; with it, you have a quantified, named impurity that can be reported and controlled.

Reference standards come in two flavours: pharmacopoeial (USP, EP, JP — typically the highest-grade, with full characterisation) and in-house. In-house standards are acceptable for non-pharmacopoeial impurities provided you can demonstrate identity by NMR, mass spec, and elemental analysis, and provided you can defend the purity assignment.

Building an Impurity-Standards Library

A regulatory-mature API manufacturer maintains a working library of reference standards covering every identified impurity in their product. This includes process impurities (from synthesis), degradation products (from stability), and metabolite-related compounds where relevant. The investment pays back the first time you face an FDA observation about an unidentified peak — and several times after that.